Repligen Co. (NASDAQ:RGEN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Repligen Co. (NASDAQ:RGEN) have received an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $197.75.

Several equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. KeyCorp increased their target price on shares of Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Finally, Stifel Nicolaus upped their price objective on shares of Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd.

Insider Activity

In related news, COO James Bylund sold 4,373 shares of the stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the transaction, the chief operating officer now directly owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Repligen news, COO James Bylund sold 4,373 shares of the firm’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the sale, the chief operating officer now owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Karen A. Dawes sold 1,000 shares of the stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the transaction, the director now owns 87,367 shares of the company’s stock, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock valued at $5,039,532 over the last quarter. Corporate insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

Hedge funds have recently bought and sold shares of the company. CWM LLC increased its position in shares of Repligen by 19.9% in the first quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 60 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Repligen by 0.3% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,178 shares of the biotechnology company’s stock worth $3,805,000 after purchasing an additional 62 shares in the last quarter. abrdn plc raised its position in shares of Repligen by 1.4% during the 4th quarter. abrdn plc now owns 5,192 shares of the biotechnology company’s stock worth $934,000 after purchasing an additional 71 shares during the last quarter. Commerce Bank lifted its stake in Repligen by 4.5% in the 4th quarter. Commerce Bank now owns 1,683 shares of the biotechnology company’s stock valued at $303,000 after buying an additional 72 shares in the last quarter. Finally, Quadrant Capital Group LLC increased its position in Repligen by 15.1% during the fourth quarter. Quadrant Capital Group LLC now owns 649 shares of the biotechnology company’s stock worth $117,000 after buying an additional 85 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Performance

NASDAQ:RGEN opened at $168.04 on Tuesday. Repligen has a 52 week low of $110.45 and a 52 week high of $211.13. The company has a fifty day simple moving average of $180.34 and a two-hundred day simple moving average of $174.47. The company has a quick ratio of 5.24, a current ratio of 6.35 and a debt-to-equity ratio of 0.26. The company has a market cap of $9.39 billion, a price-to-earnings ratio of 672.19, a price-to-earnings-growth ratio of 5.58 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The company had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. During the same quarter last year, the company earned $0.64 EPS. Repligen’s revenue for the quarter was down 17.1% compared to the same quarter last year. As a group, equities analysts anticipate that Repligen will post 1.46 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.